GO:0031267 small GTPase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031267 small GTPase binding is a molecular function defined as binding to a small monomeric GTPase, covering interactions with Ras, Rho, Rab, Ran, Arf and Ral family proteins.
• Small GTPases act as molecular switches that cycle between GDP-bound inactive and GTP-bound active states, and their binding partners decode this switch to control signaling.
• The function is central to membrane trafficking, cytoskeletal dynamics, nuclear transport and cell proliferation, and its dysregulation is linked to cancer and other diseases.
• Binding specificity is determined by the switch regions of the GTPase and by the structural motifs of the interacting protein, often at membrane surfaces.
• Key experimental approaches include in vitro reconstitution, GTPase activity assays, and CRISPR-based knockout, point mutation, knock-in and overexpression models.
• EDITGENE provides end-to-end CRISPR services to dissect small GTPase binding mechanisms and their disease relevance.
Description
GO:0031267 small GTPase binding is a molecular function that describes the binding of a protein to a small monomeric GTPase. Small GTPases, including Ras, Rho, Rab, Ran, Arf and Ral family members, function as binary molecular switches that cycle between an inactive GDP-bound state and an active GTP-bound state. The binding event is the fundamental step through which effector proteins, regulators and scaffolds interpret the GTPase switch to propagate signals. Because this function is shared by hundreds of proteins and is involved in nearly every aspect of cell biology, it is a recurring node in functional genomics and drug discovery. Researchers study small GTPase binding to understand how cells control processes such as vesicle trafficking, cytoskeletal remodeling, nuclear import and cell cycle progression. The interaction is not a simple static event; it is regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDIs), and it often occurs at membrane surfaces where the GTPase is anchored. Recent work has emphasized that the membrane environment and supramolecular organization of GTPases influence binding specificity and signaling output. From a disease perspective, abnormal small GTPase signaling is implicated in cancer, developmental disorders and neurodegeneration, making the binding function a high-value target for mechanistic and therapeutic studies. This article integrates the QuickGO definition with verified literature to provide a research-grade overview of GO:0031267, its key genes, regulatory logic, disease links and the CRISPR-based methods used to interrogate it.
small GTPase binding At A Glance
| GO ID | GO:0031267 |
|---|---|
| GO term | small GTPase binding |
| Ontology | molecular_function |
| Definition | Binding to a small monomeric GTPase. |
| Synonyms | ADP-ribosylation factor binding, ARF binding, GTP-Ral binding, GTP-Rho binding, Rab escort protein activity, Rab GTPase binding, Rab interactor activity, Rac GTPase binding, Ral GTPase binding, Ran-binding protein, Ran GTPase binding, Ran protein binding, Ras GTPase binding, Ras interactor activity, REP, Rho GTPase binding |
| Major function | Decoding the GDP/GTP switch of small GTPases to propagate signals in trafficking, cytoskeleton and nuclear transport. |
| Related regulators | GEFs, GAPs and GDIs control the nucleotide state and accessibility of the GTPase. |
| Membrane context | Many small GTPases are peripherally bound to membranes, and binding often occurs at membrane surfaces. |
| Disease relevance | Altered small GTPase signaling is linked to cancer, developmental disorders and other pathologies. |
What Is GO:0031267?
According to the Gene Ontology, GO:0031267 small GTPase binding is the molecular function of binding to a small monomeric GTPase. This includes binding to any member of the Ras superfamily of small GTPases, such as Ras, Rho, Rab, Ran, Arf and Ral proteins, and it encompasses synonyms like Ras GTPase binding, Rho GTPase binding, Rab GTPase binding, Ran GTPase binding, Arf binding and Ral GTPase binding. The function is performed by effector proteins, regulators and scaffolding molecules that recognize the GTP-bound or GDP-bound conformation of the GTPase, often through switch I and switch II regions.
Why Is small GTPase binding Important in Cell Biology?
Small GTPase binding is important because it is the molecular interface through which cells convert the nucleotide state of a GTPase into a specific biological outcome. Nearly all small GTPase functions, including vesicle transport, cytoskeletal organization, cell polarity and nuclear import, require the recruitment of binding partners. Because these interactions are highly specific and often dysregulated in disease, they are attractive targets for both basic research and therapeutic intervention.
• Controls vesicle trafficking and organelle identity through Rab and Arf family interactions.
• Regulates actin and microtubule dynamics via Rho and Rac binding proteins.
• Mediates nuclear transport through Ran-binding proteins.
• Coordinates cell proliferation and survival signaling through Ras effectors.
• Is frequently altered in cancer, where mutations in small GTPases or their regulators drive oncogenesis.
• Provides a mechanistic basis for understanding developmental disorders linked to GTPase signaling.
• Enables in vitro reconstitution studies that define minimal requirements for GTPase regulation.
• Supports drug discovery efforts targeting protein-protein interactions at the GTPase interface.
• Serves as a paradigm for studying molecular switch mechanisms in cell biology.
• Offers a rich source of targets for CRISPR-based functional genomics.
Molecular Mechanism of small GTPase binding
Nucleotide-dependent conformational switch
In simple terms: Small GTPases change shape depending on whether they carry GDP or GTP, and binding partners read this shape.
Small GTPases cycle between an inactive GDP-bound state and an active GTP-bound state, and the switch I and switch II regions undergo conformational changes that are recognized by binding partners. The GTP-bound form is typically the one that engages effector proteins, while the GDP-bound form is bound by GDIs or remains inactive. This nucleotide-dependent switch is the core of GO:0031267, as binding specificity is often determined by the conformation of these switch regions.
Membrane anchoring and spatial organization
In simple terms: Many small GTPases attach to membranes, and this positioning helps them find their binding partners.
Small GTPases are often peripherally associated with membranes through lipid modifications or polybasic regions, and this membrane anchoring concentrates them at specific cellular locations. The membrane surface acts as a platform where GTPases and their binding partners assemble into signaling hubs. Recent studies highlight that the molecular determinants of membrane binding and the supramolecular organization of GTPases influence the efficiency and specificity of downstream interactions.
Regulation by GEFs, GAPs and GDIs
In simple terms: Helper proteins turn the switch on or off by controlling GDP/GTP exchange or by holding the GTPase in an inactive state.
Guanine nucleotide exchange factors (GEFs) promote the release of GDP and loading of GTP, thereby activating the GTPase and enabling effector binding. GTPase-activating proteins (GAPs) accelerate GTP hydrolysis, returning the GTPase to its inactive state and terminating binding. Guanine nucleotide dissociation inhibitors (GDIs) sequester the GDP-bound form and prevent membrane association, adding another layer of control. These regulators are essential for the dynamic nature of GO:0031267.
Effector recognition and downstream signaling
In simple terms: Once the GTPase is active, effector proteins bind and pass the signal along.
Effector proteins contain binding domains that selectively recognize the GTP-bound conformation of a specific small GTPase, leading to activation of downstream pathways. For example, Ras effectors such as Raf kinases propagate proliferative signals, while Rho family effectors control cytoskeletal remodeling. The specificity of these interactions is encoded in the structural complementarity between the effector and the GTPase switch regions.
In vitro reconstitution of binding and regulation
In simple terms: Scientists can rebuild these interactions in test tubes to study them precisely.
In vitro reconstitution using purified GTPases, GEFs, GAPs and effectors allows researchers to measure binding kinetics, nucleotide exchange and hydrolysis under defined conditions. Such systems have revealed minimal requirements for GTPase regulation and have been used to test the effects of mutations. These approaches complement cellular studies and provide quantitative parameters for modeling the binding function.
Key Genes Involved in GO:0031267 small GTPase binding
The following genes encode small GTPases and their binding partners that collectively define GO:0031267 small GTPase binding.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HRAS | Ras family GTPase; binds effectors to drive proliferation | Oncogene; model for studying effector binding and cancer |
| KRAS | Ras family GTPase; central in MAPK signaling | Frequently mutated in cancer; target for binding studies |
| NRAS | Ras family GTPase; regulates growth and survival | Oncogene; used in knockout and point-mutation models |
| RHOA | Rho family GTPase; controls actin cytoskeleton | Binds effectors like ROCK; studied in cell motility |
| RAC1 | Rho family GTPase; regulates lamellipodia and NADPH oxidase | Key in cytoskeletal dynamics and cancer |
| CDC42 | Rho family GTPase; controls polarity and filopodia | Model for binding specificity and developmental disorders |
| RAB5A | Rab family GTPase; early endosome trafficking | Binds effectors such as EEA1; studied in endocytosis |
| RAB7A | Rab family GTPase; late endosome/lysosome trafficking | Model for membrane contact and lipid remobilization |
| ARL8B | Arf-like GTPase; lysosome positioning and lipid droplet contact | Binds effectors to mediate lipid delivery to lysosomes |
| RAN | Ran GTPase; nuclear import/export | Binds RanBP1 and importins; studied in nuclear transport |
| ARF1 | Arf family GTPase; COPI vesicle formation | Binds coat proteins; model for membrane trafficking |
| RALA | Ral family GTPase; exocytosis and tumorigenesis | Binds RalBP1 and Sec5; studied in cancer |
| RALB | Ral family GTPase; vesicle trafficking | Effector binding in exocytosis and cancer |
| RAB27A | Rab family GTPase; secretory granule transport | Binds effectors like Slp2-a; studied in secretion |
| RAB11A | Rab family GTPase; recycling endosome | Binds FIP3; model for recycling |
| RHOQ | Rho family GTPase; exocytosis and insulin signaling | Binds effectors in glucose transport |
| RAP1A | Ras family GTPase; cell adhesion | Binds RAPL and AF-6; studied in integrin signaling |
How Is small GTPase binding Regulated?
The binding of small GTPases to their partners is tightly regulated by three main classes of proteins: GEFs, GAPs and GDIs. GEFs catalyze the exchange of GDP for GTP, switching the GTPase to its active conformation that is competent for effector binding. GAPs stimulate the intrinsic GTP hydrolysis activity, thereby inactivating the GTPase and terminating binding. GDIs bind to the GDP-bound form, extract it from membranes and keep it in an inactive cytosolic pool. Additionally, post-translational modifications such as phosphorylation and lipid modification can influence the localization and binding properties of small GTPases. The membrane environment and supramolecular organization further modulate these interactions, as reviewed in the context of peripheral binding. In vitro reconstitution studies have provided quantitative insights into how these regulators control the nucleotide cycle and binding events.
small GTPase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer (pancreatic, lung, colorectal) | Knockout and point-mutation (G12D) cell lines |
| RHOA | Cancer and developmental disorders | Knockout and overexpression models |
| RAB7A | Neurodegeneration and lysosomal storage | Knock-in of disease-associated mutations |
| ARL8B | Metabolic dysfunction and lipid trafficking | Knockout and tagged knock-in for imaging |
| RAN | Cancer and nuclear transport defects | Point mutation and overexpression |
Cancer
Dysregulation of small GTPase binding is a hallmark of many cancers. Mutations in RAS genes (HRAS, KRAS, NRAS) lock the GTPase in the active state, leading to constitutive effector binding and uncontrolled proliferation. Abnormal epigenetic regulation of small GTPases has been reported in glioma, affecting their expression and downstream signaling. Targeting the interaction between oncogenic GTPases and their effectors is a major therapeutic strategy.
Neurodegeneration and developmental disorders
Small GTPases such as RAB7A and RAB5A are critical for neuronal trafficking, and defects in their binding partners can lead to neurodegenerative phenotypes. Rho family GTPases regulate neuronal morphogenesis, and mutations affecting their binding interfaces have been linked to developmental disorders. The precise control of GTPase binding is essential for neuronal function and survival.
Metabolic and lysosomal storage disorders
ARL8B mediates lipid droplet contact and delivery to lysosomes for lipid remobilization, and its dysfunction may contribute to metabolic imbalances. Rab7A is required for late endosome/lysosome function, and its impairment is associated with lysosomal storage diseases. These examples illustrate how small GTPase binding directly impacts cellular metabolism and organelle homeostasis.
From small GTPase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a GTPase-binding protein affect signaling? | CRISPR knockout cell line |
| Does a specific point mutation alter binding affinity? | CRISPR point-mutation knock-in |
| Where does the binding occur in live cells? | Tagged knock-in with fluorescent protein |
| Does overexpression drive oncogenic transformation? | CRISPR overexpression (CRISPRa) |
| Which genes modulate GTPase binding in a genome-wide screen? | CRISPR library screening |
| Can we reconstitute the binding in vitro? | Purified recombinant proteins and in vitro reconstitution |
How to Study the small GTPase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro reconstitution | Binding kinetics and nucleotide exchange | Mechanistic studies of GTPase regulation |
| GTP hydrolysis assay | GAP activity and intrinsic hydrolysis | Characterizing regulators |
| GEF exchange assay | Nucleotide exchange rate | Identifying GEF specificity |
| CRISPR knockout | Loss-of-function phenotype | Gene function in signaling |
| CRISPR point mutation | Effect of specific amino acid change | Dissecting binding interfaces |
| Tagged knock-in | Localization and dynamics | Live-cell imaging |
| CRISPR library screen | Genome-wide modifiers | Discovery of new pathway components |
| Proximity labeling proteomics | Interactome | Identifying novel binding partners |
In vitro reconstitution and binding assays
In vitro reconstitution using purified small GTPases, GEFs, GAPs and effectors allows direct measurement of binding kinetics and nucleotide exchange. Techniques such as isothermal titration calorimetry, surface plasmon resonance and fluorescence polarization can quantify affinity and specificity. These methods provide mechanistic insights that complement cellular studies.
GTPase activity and nucleotide exchange assays
GTPase activity can be monitored using radioactive GTP hydrolysis assays or fluorescent nucleotide analogs. GEF and GAP activities are measured by changes in nucleotide exchange or hydrolysis rates. These assays are essential for understanding how regulators control the binding-competent state of the GTPase.
CRISPR-based functional genomics
CRISPR knockout, point mutation, knock-in and overexpression screens enable systematic interrogation of genes involved in small GTPase binding. Library screening can identify modifiers of GTPase signaling and reveal synthetic lethal interactions. These approaches are powerful for discovering new components of the binding network.
Imaging and proteomics
Live-cell imaging of fluorescently tagged GTPases and binding partners reveals spatiotemporal dynamics of the interaction. Proximity labeling and affinity purification coupled to mass spectrometry can identify novel binding partners. These methods bridge structural and cellular scales.
How CRISPR Can Be Used to Study GO:0031267 small GTPase binding
Knockout
CRISPR knockout of a small GTPase or its binding partner can abolish the interaction and reveal its cellular function. Knockout cell lines are valuable for studying loss-of-function phenotypes in signaling, trafficking and proliferation. They also serve as clean backgrounds for rescue experiments.
Point Mutation
CRISPR point mutation allows the introduction of specific amino acid substitutions that disrupt or enhance binding without affecting protein expression. This is particularly useful for dissecting the contribution of individual residues in the switch regions or effector interfaces. Point-mutation models can mimic disease-associated mutations.
Knock-in
Knock-in of tagged versions of GTPases or binding partners enables visualization and biochemical isolation of the complex. Fluorescent tags allow live-cell imaging of binding dynamics, while affinity tags facilitate proteomic analysis. Knock-in models preserve endogenous regulation, providing more physiological relevance.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can elevate the levels of a GTPase or binding partner to study gain-of-function effects. Overexpression is often used to amplify signaling and to test oncogenic potential. It complements knockout studies by providing a reciprocal perturbation.
How EDITGENE Supports small GTPase binding Research
Researchers studying small GTPase binding-related genes often need to determine whether a candidate gene is causally involved in a specific signaling pathway, and CRISPR-based models provide the most direct way to establish causality. EDITGENE offers a comprehensive suite of services to generate and characterize such models.
Contact EDITGENE today to design your custom CRISPR model for small GTPase binding research.
Frequently Asked Questions About small GTPase binding
What is GO:0031267 small GTPase binding?
GO:0031267 is a Gene Ontology molecular function term defined as binding to a small monomeric GTPase, covering interactions with Ras, Rho, Rab, Ran, Arf and Ral family proteins.
What genes are involved in small GTPase binding?
Key genes include HRAS, KRAS, NRAS, RHOA, RAC1, CDC42, RAB5A, RAB7A, ARL8B, RAN, ARF1, RALA, RALB, RAB27A, RAB11A, RHOQ and RAP1A, which encode GTPases or their binding partners.
How is small GTPase binding regulated?
It is regulated by GEFs, GAPs and GDIs that control the nucleotide state and membrane association of the GTPase.
Why is small GTPase binding important in cancer?
Mutations that lock GTPases in the active state lead to constitutive effector binding and uncontrolled proliferation, making this function a therapeutic target.
What methods are used to study small GTPase binding?
Methods include in vitro reconstitution, GTP hydrolysis assays, CRISPR knockout, point mutation, knock-in, overexpression and library screening.
What is the role of ARL8B in small GTPase binding?
ARL8B is an Arf-like GTPase that mediates lipid droplet contact and delivery to lysosomes for lipid remobilization.
How do GEFs and GAPs affect small GTPase binding?
GEFs promote GTP loading and activation, while GAPs accelerate GTP hydrolysis to terminate binding.
Can CRISPR be used to study small GTPase binding?
Yes, CRISPR knockout, point mutation, knock-in and overexpression are widely used to dissect the function of GTPases and their binding partners.
What diseases are linked to small GTPase binding?
Diseases include cancer, neurodegeneration, developmental disorders and metabolic/lysosomal storage disorders.
What is the definition of small GTPase binding according to QuickGO?
The QuickGO definition is binding to a small monomeric GTPase, with synonyms including Ras GTPase binding, Rho GTPase binding, Rab GTPase binding, Ran GTPase binding and Arf binding.
Conclusion
GO:0031267 small GTPase binding is a fundamental molecular function that underpins diverse cellular processes, from vesicle trafficking to cytoskeletal dynamics and nuclear transport. Its regulation by GEFs, GAPs and GDIs ensures precise spatial and temporal control, and its dysregulation is implicated in cancer and other diseases. Advances in in vitro reconstitution and CRISPR-based models continue to illuminate the mechanistic details of these interactions. EDITGENE provides the tools and expertise to accelerate research on small GTPase binding and its role in health and disease.
References
- 1. Peurois F et al.. 2019. Small GTPase peripheral binding to membranes: molecular determinants and supramolecular organization.. Biochem Soc Trans 47(1):13-22 PMID: 30559268
- 2. Reiner DJ et al.. 2018. Small GTPases.. WormBook 2018:1-65 PMID: 27218782
- 3. Zhang M et al.. 2025. The role of abnormal epigenetic regulation of small GTPases in glioma (Review).. Int J Oncol 67(2) PMID: 40613212
- 4. Menon D et al.. 2023. ARL8B mediates lipid droplet contact and delivery to lysosomes for lipid remobilization.. Cell Rep 42(10):113203 PMID: 37777960
- 5. Bos JL et al.. 2007. GEFs and GAPs: critical elements in the control of small G proteins.. Cell 129(5):865-77 PMID: 17540168
- 6. Cherfils J. 2023. Small GTPase signaling hubs at the surface of cellular membranes in physiology and disease.. FEBS Lett 597(6):717-720 PMID: 36974464
- 7. Faulkner B et al.. 2025. Methods for Controlling Small GTPase Activity.. Chembiochem 26(13):e202500156 PMID: 40396811
- 8. Loose M et al.. 2023. In vitro reconstitution of small GTPase regulation.. FEBS Lett 597(6):762-777 PMID: 36448231
